The global oral biologics & biosimilar drugs market size is expected to grow from $4.06 billion in 2021 to $4.91 billion in 2022 at a compound annual growth rate (CAGR) of 21%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oral biologics and biosimilar drugs market is expected to reach $10.41 billion in 2026 at a CAGR of 20.7%.
What is the Global Oral Biologics & Biosimilar Drugs Market?
The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer. Biologics are drugs made from living cells using highly complex technology while biosimilars are created to function similarly to biologics but are not identical to biologics. Biosimilars offer active properties as any licensed biologic drug. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.
Get a Sample of the global oral biologics & biosimilar drugs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&&type=smp
What drives the Global Oral Biologics & Biosimilar Drugs Market?
The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market.
Get the full global oral biologics & biosimilar drugs industry report here:
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report
Global Oral Biologics & Biosimilar Drugs Market Segments
The global oral biologics & biosimilar drugs market is segmented:
By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
By Disease: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Oral Biologics & Biosimilar Drugs Global Market Report 2022provides market size and growth forecasts for the global oral biologics & biosimilar drugs market, global oral biologics & biosimilar drugs market share, oral biologics & biosimilar drugs market segments and geographies, oral biologics & biosimilar drugs market competitive landscape including leading competitors’ revenues, profiles and market shares. The oral biologics & biosimilar drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Oral Biologics & Biosimilar Drugs Industry Playersinclude Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline Plc., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and RocheBased on industry trends and company analysis, the report explains a number of strategies for companies in the market.
